 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...197198199200201202203204205206207208209» |
- AiTan (rivoceranib) / HLB Bio Group
New trial, Combination therapy, Metastases: ARCAP: Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer (clinicaltrials.gov) - Dec 20, 2016
P=N/A, N=40, Enrolling by invitation, Sponsor: Sichuan Provincial People's Hospital
- Opdivo (nivolumab) / Ono Pharma, BMS, plinabulin (BPI 2358) / BeyondSpring
Trial initiation date, PD(L)-1 Biomarker: Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 15, 2016
P1/2, N=39, Not yet recruiting, Sponsor: University of Washington
Initiation date: Aug 2016 --> Feb 2017
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Dec 15, 2016
P2, N=25, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- || AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change, Trial primary completion date: A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) - Dec 15, 2016
P1, N=96, Enrolling by invitation, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Initiation date: Aug 2016 --> Feb 2017 N=36 --> 96 | Trial primary completion date: Dec 2016 --> Sep 2017
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2/3 trial: A Study to Evaluate SHR-1210 in Subjects With Advanced HCC (clinicaltrials.gov) - Dec 12, 2016
P2/3, N=60, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib for Advanced Non-squamous Head and Neck Cancer (clinicaltrials.gov) - Dec 12, 2016
P2, N=30, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- AiTan (rivoceranib) / HLB Bio Group
Enrollment open: Apslpanc: Apatinib as Second-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 2, 2016
P2, N=30, Recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
N=36 --> 96 | Trial primary completion date: Dec 2016 --> Sep 2017 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer (clinicaltrials.gov) - Dec 2, 2016
P2, N=60, Not yet recruiting, Sponsor: First Hospitals affiliated to the China PLA General Hospital
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial primary completion date: Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors (clinicaltrials.gov) - Nov 29, 2016
P1, N=70, Recruiting, Sponsor: Hengrui Therapeutics, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Dec 2017
- Opdivo (nivolumab) / Ono Pharma, BMS, plinabulin (BPI 2358) / BeyondSpring
Enrollment open, Trial initiation date: Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Nov 29, 2016
P1, N=38, Recruiting, Sponsor: Lyudmila Bazhenova, M.D.
Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Aug 2016
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 29, 2016
P2, N=48, Recruiting, Sponsor: Wuling Ou
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Poetry-1: Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (clinicaltrials.gov) - Nov 29, 2016
P2, N=43, Recruiting, Sponsor: Yuhong Li
- |||||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P3 trial: PHENIX: A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Nov 25, 2016
P3, N=350, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment status: A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) - Nov 23, 2016
P1, N=36, Enrolling by invitation, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Aug 2016 Recruiting --> Enrolling by invitation
- AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment status: A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma (clinicaltrials.gov) - Nov 23, 2016
P1, N=36, Enrolling by invitation, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Enrolling by invitation Recruiting --> Enrolling by invitation
- AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment status: A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) - Nov 23, 2016
P1, N=45, Enrolling by invitation, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Enrolling by invitation Recruiting --> Enrolling by invitation
- AiTan (rivoceranib) / HLB Bio Group
Enrollment open: ADVANCE: ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy (clinicaltrials.gov) - Nov 1, 2016
P2, N=103, Recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed: A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients (clinicaltrials.gov) - Oct 28, 2016
P1, N=24, Active, not recruiting, Sponsor: Incyte Europe S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. (clinicaltrials.gov) - Oct 26, 2016
P2, N=30, Recruiting, Sponsor: Zhejiang Cancer Hospital
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma (clinicaltrials.gov) - Oct 25, 2016
P2, N=50, Not yet recruiting, Sponsor: Shanghai Proton and Heavy Ion Center
- AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer (clinicaltrials.gov) - Oct 25, 2016
P2, N=30, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer (clinicaltrials.gov) - Oct 25, 2016
P1/2, N=30, Recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New P1 trial: A Study of SHR-1314 in Healthy Subjects (clinicaltrials.gov) - Oct 16, 2016
P1, N=40, Recruiting, Sponsor: Atridia Pty Ltd.
- AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Metastases: A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck (clinicaltrials.gov) - Oct 3, 2016
P2, N=60, Recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Trial primary completion date: Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer (clinicaltrials.gov) - Sep 21, 2016
P2/3, N=48, Recruiting, Sponsor: Hebei Medical University
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2016 --> Dec 2016
- AiRuiKa (camrelizumab) / HLB Bio Group
Trial primary completion date: A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients (clinicaltrials.gov) - Sep 20, 2016
P1, N=27, Recruiting, Sponsor: Incyte Europe S
Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: Jul 2016 --> Dec 2017
- AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment open: A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Sep 15, 2016
P1, N=30, Recruiting, Sponsor: Atridia Pty Ltd.
Trial primary completion date: Jul 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment open: A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer (clinicaltrials.gov) - Sep 15, 2016
P1, N=42, Recruiting, Sponsor: Atridia Pty Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| plinabulin (BPI 2358) / BeyondSpring
Trial initiation date, Trial primary completion date: DUBLIN-3: Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (clinicaltrials.gov) - Sep 8, 2016
P3, N=550, Recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Initiation date: Jul 2015 --> Jun 2016 | Trial primary completion date: Nov 2017 --> Nov 2018
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P1 trial: Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects (clinicaltrials.gov) - Sep 8, 2016
P1, N=14, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
New P1 trial: Multiple Dose Study of SHR4640 in Healthy Subjects (clinicaltrials.gov) - Sep 7, 2016
P1, N=48, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006) (clinicaltrials.gov) - Aug 25, 2016
P2, N=30, Active, not recruiting, Sponsor: Beijing Cancer Hospital
- || AiTan (rivoceranib) / HLB Bio Group
New P3 trial: Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin (clinicaltrials.gov) - Aug 23, 2016
P3, N=100, Not yet recruiting, Sponsor: Third Military Medical University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: ADVANCE: ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy (clinicaltrials.gov) - Aug 21, 2016
P2, N=103, Not yet recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Platinum resistant: Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer (clinicaltrials.gov) - Aug 16, 2016
P2, N=68, Recruiting, Sponsor: Sun Yat-sen University
- |||||||||| pregabalin sustained-release / Jiangsu Hengrui Pharma
New P3 trial: The Efficacy and Safety of Pregabalin Release Tablets for the Treatment of Fibromyalgia (clinicaltrials.gov) - Aug 15, 2016
P3, N=240, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial: OECTAPGAMPC: A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 11, 2016
P2, N=30, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- AiTan (rivoceranib) / HLB Bio Group
New trial, Monotherapy: Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC (clinicaltrials.gov) - Aug 2, 2016
P=N/A, N=60, Not yet recruiting, Sponsor: Jiangsu ShengDiYa Medicine Co., Ltd.
- AiTan (rivoceranib) / HLB Bio Group
New P1/2 trial: Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma (clinicaltrials.gov) - Jul 28, 2016
P1/2, N=40, Not yet recruiting, Sponsor: The First People's Hospital of Lianyungang
- | AiTan (rivoceranib) / HLB Bio Group
New P1/2 trial, Metastases: Study of Apatinib and MASCT in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 27, 2016
P1/2, N=60, Not yet recruiting, Sponsor: The First People's Hospital of Lianyungang
- Opdivo (nivolumab) / Ono Pharma, BMS, plinabulin (BPI 2358) / BeyondSpring
New P1/2 trial, PD(L)-1 Biomarker: Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 27, 2016
P1/2, N=39, Not yet recruiting, Sponsor: University of Washington
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Trial primary completion date: A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=128, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Initiation date: Jul 2015 --> Jun 2016 | Trial primary completion date: Nov 2017 --> Nov 2018 Trial primary completion date: Jun 2016 --> Oct 2016
- AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment change: A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jul 19, 2016
P1, N=30, Not yet recruiting, Sponsor: Atridia Pty Ltd.
Trial primary completion date: Jun 2016 --> Oct 2016 N=21 --> 30
- AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment change: A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer (clinicaltrials.gov) - Jul 19, 2016
P1, N=42, Not yet recruiting, Sponsor: Atridia Pty Ltd.
N=21 --> 30 N=27 --> 42
- | AiTan (rivoceranib) / HLB Bio Group
New P1 trial: Effect of Rifampicin on the Pharmacokinetics of Apatinib (clinicaltrials.gov) - Jul 19, 2016
P1, N=20, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
New P1 trial: Effect of Itraconazole on the Pharmacokinetics of Apatinib (clinicaltrials.gov) - Jul 18, 2016
P1, N=20, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment open: SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer (clinicaltrials.gov) - Jul 18, 2016
P3, N=574, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=27 --> 42 Not yet recruiting --> Recruiting
- ||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial: A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation (clinicaltrials.gov) - Jul 15, 2016
P2, N=55, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients (clinicaltrials.gov) - Jul 12, 2016
P2, N=53, Recruiting, Sponsor: Shoucheng Ma
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers (clinicaltrials.gov) - Jul 7, 2016
P1, N=30, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.